✦ LIBER ✦

Sirolimus and mycophenolate mofetil after liver transplantation

✍ Scribed by Daniela Kniepeiss; Florian Iberer; Barbara Grasser; Silvia Schaffellner; Karl-Heinz Tscheliessnigg

Publisher: Springer
Year: 2003
Tongue: English
Weight: 284 KB
Volume: 16
Category: Article
ISSN: 0934-0874
DOI: 10.1007/s00147-003-0579-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of mycophenolate mofeti

Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine

✍ Steven J. Lobritto; Philip Rosenthal; Rene Bouw; Mimi Leung; Paul Snell; Richard 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

There are few pharmacokinetic data for mycophenolate mofetil (MMF) when used in combination with cyclosporine (CsA) in pediatric liver transplant recipients. The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF req

Pharmacokinetics of mycophenolic acid in

Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

✍ Ashok Jain; Raman Venkataramanan; Tai Kwong; Ravi Mohanka; Mark Orloff; Peter Ab 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients. Such information is limited in liver transplant (LTx) patients. The present study

Mycophenolate mofetil monotherapy in liv

Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience

✍ Kyrsten D. Fairbanks; Paul J. Thuluvath 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

The long-term use of calcineurin inhibitors (CIs) is associated with significant morbidity in liver transplant recipients. Although mycophenolate mofetil (MMF) is well tolerated, two small studies reported an unacceptable rate of acute allograft rejection in liver transplant recipients receiving MMF

Mycophenolate mofetil in combination wit

Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation

✍ Georges-Philippe Pageaux; Lionel Rostaing; Yvon Calmus; Christophe Duvoux; Clair 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was

Long-term effects of calcineurin inhibit

Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation

✍ Caroline Créput; Frederique Blandin; Benjamin Deroure; Bruno Roche; Faouzi Salib 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression after liver transplantation. However, CNI treatment is frequently associated with chronic renal failure (CRF). The reduction or interruption of CNI may reduce renal failure. We prospectively studied 49 liver recipients treated wi

Elective withdrawal of mycophenolate mof

Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone

✍ Cornelis G. ter Meulen; Peter J. H. Smak Gregoor; Willem Weimar; Luuk B. Hilbran 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 49 KB